CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

According to analysts at Fortune Business Insights, two-thirds of these centers are owned by one of three companies: CSL Plasma, Grifols, and BioLife. Even before the pandemic hit, global demand ...

CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...

Some of the bigger plasma donation centers include CSL Plasma, BioLife Plasma Services ... slightly from having to pump the blood into the machine, and that “when you get the liquids pumped ...

which is now known as global biotechnology leader CSL Behring; US plasma collector Nabi, which helped to form the world’s premier plasma collection company in CSL Plasma; the Novartis influenza ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...